Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOC 1044 in DMD with Exon 44 Skipping Mutations
NCT07587242Phase 3Recruiting
- Sponsor
- Avidity Biosciences
- Start
- Sep 2026
- Primary completion
- May 2029
- Modality
- Antisense DNA, Antibody Conjugates, Conjugated siRNA
- Countries
- 8
01
Overview
A Phase 3 trial of delpacibart zotadirsen in Duchenne muscular dystrophy (DMD), sponsored by Avidity Biosciences. Started Sep 2026; status: recruiting.
02
Drugs
delpacibart zotadirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07587242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587242.